Prof. Kinfe Ken Redda
NIH/NIMHD, Research Infrastructure Core (RIC) Leader
Florida A&M University
USA
Dr. Redda graduated from the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (U of A), Edmonton, Canada with a Ph.D. degree in Medicinal Chemistry in 1978. He successfully completed two years of postdoctoral fellowship in synthetic medicinal chemistry at the U of A and Dalhousie University College of Pharmacy in Halifax, Nova Scotia. Dr. Redda received his appointment as an Assistant Professor of Medicinal Chemistry at the College of Pharmacy, University of Puerto Rico (UPR) in San Juan in 1980. He was actively engaged in teaching, research and service at UPR. He accepted an offer as an Associate Professor of Medicinal Chemistry in the College of Pharmacy and Pharmaceutical Sciences, Florida A&M University (FAMU) in Tallahassee, Florida in 1985. Dr. Redda is continuing to serve FAMU in teaching, research, public service and academic administrative capacities until now. He rose through the ranks as a professor, Director of �Biomedical Research Programs on Campus� (19 years), FAMU Associate Vice President for Research and finally as the institution is Vice President for Research (2010-2015). Currently, he is serving FAMU as Professor Emeritus and is carrying out cancer-research activities that are funded by two NIH grants. Throughout his research activities, Dr. Redda generated over US $71.0 Million as a PI in research & training grants funding, obtained mainly from US-NIH, NASA, State of Florida, Eli Lilly and Pfizer. Dr. Redda owns nine US Patents, and he has authored numerous peer-reviewed and indexed papers and his research findings were presented in about 130 national and international scientific meetings. His research involves the design and synthesis of nitrogen heterocycles as anti-breast cancer agents. Dr. Redda is a member of many state and national professional and scientific associations. In this capacity, he is a regular manuscript reviewer of articles submitted for publication to major scientific journals. He also served in several regular and ad hoc NIH review panels over the past 30+ years.
